Myriad Genetics Inc
- Last sale
- Nov 12, 2026 · -0.53%
- Market cap
- $544.84M
- 95.92M shares
- Filings
- 1,046
Q3 2026−1.6% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q2 2023derivedN/M FY22 yoy
Q3 2026N/M FY25 yoy
Q3 2026+46.1% FY25 yoy
- $544.84M
- —
- 0.7×
- 2.0×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $824,500,000 | reported | |
| FY 2024 | 2024-12-31 | $837,600,000 | reported | |
| FY 2023 | 2023-12-31 | $753,200,000 | reported | |
| FY 2022 | 2022-12-31 | $678,400,000 | reported | |
| FY 2021 | 2021-12-31 | $690,600,000 | reported | |
| FY 2020 | 2020-12-31 | $557,100,000 | reported | |
| FY 2019 | 2019-06-30 | $851,100,000 | reported | |
| FY 2018 | 2018-06-30 | $743,700,000 revised | reported | |
| FY 2017 | 2017-06-30 | $728,700,000 revised | reported | |
| FY 2016 | 2016-06-30 | $740,500,000 revised | reported | |
| FY 2015 | 2015-06-30 | $722,500,000 revised | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2021 | — | $0.00 | $0.00 | — | 80.02M sh | +4.9% | 0.0% |
| FY2020 | — | $0.00 | $0.00 | — | 76.30M sh | +2.4% | 0.0% |
| FY2019 | — | $50.00M | $50.00M | — | 74.50M sh | +5.0% | 66.6% |
| FY2018 | — | $0.00 | $0.00 | — | 70.92M sh | +3.6% | 0.0% |
| FY2017 | — | $31.60M | $31.60M | — | 68.44M sh | −1.0% | 31.6% |
Segments
LineFY2025ShareChange
U.S.$768.00M93%−0.2%
RoW$56.50M6.9%−17.0%
Total$824.50M
In vitro & in vivo diagnostic substances
Myriad Genetics Inc is the 5th largest of the 20 covered companies the SEC files under this code, by revenue. SIC 2835
CompanyRevenueGrowthNet marginMarket cap
IDXXIDEXX Laboratories Inc$4.3B10.4%24.6%$55.0BQDELQuidelOrtho Corp$2.7B1.9%41.5%$728.3MLNTHLantheus Holdings, Inc.$1.5B0.5%15.2%$6.6BNEOGNeogen Corp$870.4M2.7%0.9%$2.4B
MYGNMyriad Genetics Inc (this company)$824.5M1.6%44.4%$544.8M
NTLAIntellia Therapeutics, Inc.$67.7M16.9%609.9%$1.5BTKNOAlpha Teknova, Inc.$40.5M7.4%42.6%$521.8MICCCImmucell Corp$27.6M4.3%3.8%$89.6MAWHLAspira Women's Health Inc.$9.2M0.4%138.7%$16.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR